Nevertheless, several HER3-targeted antibodies are being tested in clinical trials for peripheral tumours15,21 but may be limited by the resistance of HER3+ tumours to signal-blocking therapies15 while the BBB limits antibody access to intracerebral tumours22–24. Here, ERBB3 is linked to neoplasm.